Renal allograft biopsies in the era of C4d staining: the need for change in the Banff classification system
Open Access
- 7 December 2007
- journal article
- Published by Frontiers Media SA in Transplant International
- Vol. 21 (3), 268-275
- https://doi.org/10.1111/j.1432-2277.2007.00604.x
Abstract
C4d immunostaining in the peritubular capillaries (PTC) is a marker of antibody‐mediated rejection (AMR). We evaluated the histopathologic diagnoses of 388 renal transplant biopsies since the implementation of routine C4d immunostaining at our center. Of these, 155 (40%) biopsies had evidence of acute cellular rejection (ACR), out of which 119 (77%) had pure ACR, 31 (20%) had ACR with concomitant features of AMR, and five (3%) had ACR with focal C4d staining. Sixty‐four (16%) biopsies exhibited features of AMR [33 (52%) pure AMR, and 31(48%) concomitant AMR and ACR]. One hundred and fifty‐five (40%) biopsies had features of interstitial fibrosis and tubular atrophy (IFTA). Of these, 20 (13%) had concomitant AMR [13 (8.5%) had pure AMR and seven (4.5%) had concomitant ACR and AMR]. Creatinine at the time of biopsy was higher in patients with mixed ACR and AMR and the clinical behavior of mixed lesions is more aggressive over time. Despite having a lower serum creatinine at the time of biopsy, patients with IFTA experienced gradual decline in graft function over time. The pathologic findings in renal allograft biopsies are often mixed and mixed lesions appear to have more aggressive clinical behavior. These findings suggest the need for change in the Banff classification system to better capture the complexity of renal allograft pathologies.Keywords
This publication has 31 references indexed in Scilit:
- Antibody-mediated rejection following renal transplantationExpert Opinion on Pharmacotherapy, 2007
- Banff ’05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy (’CAN’)American Journal of Transplantation, 2007
- Treatment of early mixed cellular and humoral renal allograft rejection with tacrolimus and mycophenolate mofetilKidney International, 2007
- The classification and treatment of antibody-mediated renal allograft injury: Where do we stand?Kidney International, 2007
- The emerging role of rituximab in organ transplantationTransplant International, 2006
- Characterization of rejection episodes in patients following positive crossmatch and ABO-incompatible live donor renal transplantationTransplant International, 2006
- Transplantation across previously incompatible immunological barriersTransplant International, 2006
- C4d as a significant predictor for humoral rejection in renal allograftsClinical Transplantation, 2005
- Complement C4d deposition in transplanted kidneys: preliminary report on long-term graft survivalClinical Transplantation, 2005
- Hepatitis C, Acute Humoral Rejection, and Renal Allograft SurvivalJournal of the American Society of Nephrology, 2004